Ma D - Search Results

1

Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591).

Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, Ma D, Bander NH, Scheinberg DA, Sgouros G. Ballangrud AM, et al. Among authors: ma d. Cancer Res. 2001 Mar 1;61(5):2008-14. Cancer Res. 2001. PMID: 11280760

2

Targeted alpha particle immunotherapy for myeloid leukemia.

Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Jurcic JG, et al. Among authors: ma d. Blood. 2002 Aug 15;100(4):1233-9. Blood. 2002. PMID: 12149203 Free article. Clinical Trial.

3

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation.

McDevitt MR, Finn RD, Sgouros G, Ma D, Scheinberg DA. McDevitt MR, et al. Among authors: ma d. Appl Radiat Isot. 1999 May;50(5):895-904. doi: 10.1016/s0969-8043(98)00151-1. Appl Radiat Isot. 1999. PMID: 10214708

4

Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.

McDevitt MR, Finn RD, Ma D, Larson SM, Scheinberg DA. McDevitt MR, et al. Among authors: ma d. J Nucl Med. 1999 Oct;40(10):1722-7. J Nucl Med. 1999. PMID: 10520715 Free article.

5

An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.

McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballangrud AM, Yang WH, Finn RD, Pellegrini V, Geerlings MW Jr, Lee M, Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA. McDevitt MR, et al. Among authors: ma d. Cancer Res. 2000 Nov 1;60(21):6095-100. Cancer Res. 2000. PMID: 11085533

6

Rapid preparation of short-lived alpha particle emitting radioimmunopharmaceuticals.

Ma D, McDevitt MR, Finn RD, Scheinberg DA. Ma D, et al. Appl Radiat Isot. 2001 Oct;55(4):463-70. doi: 10.1016/s0969-8043(01)00048-3. Appl Radiat Isot. 2001. PMID: 11545498

7

Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use.

Ma D, McDevitt MR, Finn RD, Scheinberg DA. Ma D, et al. Appl Radiat Isot. 2001 Nov;55(5):667-78. doi: 10.1016/s0969-8043(01)00062-8. Appl Radiat Isot. 2001. PMID: 11573800

8

Tumor therapy with targeted atomic nanogenerators.

McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. McDevitt MR, et al. Among authors: ma d. Science. 2001 Nov 16;294(5546):1537-40. doi: 10.1126/science.1064126. Science. 2001. PMID: 11711678

9

Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.

Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V, Brechbiel MW, Scheinberg DA. Ma D, et al. Leukemia. 2002 Jan;16(1):60-6. doi: 10.1038/sj.leu.2402320. Leukemia. 2002. PMID: 11840264

10

Design and synthesis of 225Ac radioimmunopharmaceuticals.

McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA. McDevitt MR, et al. Among authors: ma d. Appl Radiat Isot. 2002 Dec;57(6):841-7. doi: 10.1016/s0969-8043(02)00167-7. Appl Radiat Isot. 2002. PMID: 12406626

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,708 results

Search Page

Filters